Juvenile neuronal ceroid lipofuscinosis (JNCL) is an autosomal recessively inherited neurodegenerative disorder that results from mutations in the CLN3 gene. JNCL is characterized by accumulation of autofluorescent lysosomal storage bodies, vision loss, seizures, progressive cognitive and motor decline, and premature death. Studies were undertaken to characterize the neuronal ceroid lipofuscinosis phenotype in a Cln3 knockout mouse model. Progressive accumulation of autofluorescent storage material was observed in brain and retina of affected mice. The Cln3 −/− mice exhibited progressively impaired inner retinal function, altered pupillary light reflexes, losses of inner retinal neurons, and reduced brain mass. Behavioral changes included reduced spontaneous activity levels and impaired learning and memory. In addition, Cln3 −/− mice had significantly shortened life spans. These phenotypic features indicate that the mouse model will be useful for investigating the mechanisms underlying the disease pathology in JNCL and provide quantitative markers of disease pathology that can be used for evaluating the efficacies of therapeutic interventions.
Introduction
The neuronal ceroid lipofuscinoses (NCLs) are autosomal recessively inherited lysosomal storage disorders associated with progressive neurodegeneration and the accumulation of autofluorescent storage bodies in various tissues (Wisniewski and Zhong, 2001 ). In humans, there are a number of forms of NCL that differ from one another in the age at which symptoms first appear, the rate of disease progression, and the patterns of symptoms (Dyken, 1988; Goebel and Wisniewski, 2004; Wisniewski and Zhong, 2001; Wisniewski et al., 2001) . Almost all NCL patients exhibit severe vision loss and progressive cognitive impairment that reflects progressive pathological changes in the central nervous system, including engorgement of neurons with storage material, brain and retinal atrophy, and generalized neuronal degeneration (Goebel and Wisniewski, 2004) . Currently there are no known treatments to delay or halt the progression of the NCLs; the development of therapeutic interventions has been impeded by the lack of defined objective markers of disease status. In humans, the different forms of NCL result from mutations in at least eight distinct genes (Goebel and Wisniewski, 2004; Siintola et al., 2006 Siintola et al., , 2007 Steinfeld et al., 2006; Wisniewski et al., 2001) .
The most prevalent form of human NCL is the juvenile type, commonly designated Batten disease. Children with this disorder typically begin to exhibit symptoms at 5 to 7 years of age and seldom live past their mid-twenties. Juvenile NCL results from mutations in the CLN3 gene which encodes a putative membrane protein of unknown function (Consortium, 1995; Kaczmarski et al., 1999; Mao et al., 2003; Mitchison et al., 1997; Phillips et al., 2005; Rakheja et al., 2004) . Animal models could be of great value in developing a better understanding of the mechanisms underlying neuropathology in JNCL and in developing therapies for this disorder. Three mouse Cln3 knockout models have been created (Cotman et al., 2002; Katz et al., 1999; Mitchison et al., 1999 ) that could be useful in developing therapeutic interventions if they exhibit quantifiable signs of disease. Experiments were performed to determine whether a homozygous Cln3 knockout mutation in mice resulted phenotypic alterations that resembled the human disease phenotype. This is the first description of a Cln3 −/− model that has been studied across the entire life spans of mice and in a mouse strain in which the phenotypic effects of mutations in other NCL genes have also been characterized.
